CHLORAPREP TRIPLE SWABSTICK Drug Patent Profile

Which patents cover Chloraprep Triple Swabstick, and what generic alternatives are available?

Chloraprep Triple Swabstick is a drug marketed by Becton Dickinson Co and is included in one NDA.

The generic ingredient in CHLORAPREP TRIPLE SWABSTICK is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Summary for CHLORAPREP TRIPLE SWABSTICK

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
DailyMed Link:	CHLORAPREP TRIPLE SWABSTICK at DailyMed

Recent Clinical Trials for CHLORAPREP TRIPLE SWABSTICK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CareFusion	Phase 3

See all CHLORAPREP TRIPLE SWABSTICK clinical trials

Pharmacology for CHLORAPREP TRIPLE SWABSTICK

Physiological Effect

Decreased Cell Wall Integrity

US Patents and Regulatory Information for CHLORAPREP TRIPLE SWABSTICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Becton Dickinson Co	CHLORAPREP TRIPLE SWABSTICK	chlorhexidine gluconate; isopropyl alcohol	SWAB;TOPICAL	021555-003	Jun 10, 2009		OTC	Yes	Yes

International Patents for CHLORAPREP TRIPLE SWABSTICK

See the table below for patents covering CHLORAPREP TRIPLE SWABSTICK around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2200532	DOSAGE APPLICATOR OF BACTERICIDAL SUBSTANCE AND METHOD FOR ITS MANUFACTURING
China	1231602
Austria	262323
Germany	69728280
Brazil	9712117
Canada	2263158	APPLICATEUR UNI-DOSE DE GLUCONATE DE CHLORHEXADINE (GCH) A DUREE DE CONSERVATION PROLONGEE (UNIT DOSE CHLORHEXADINE GLUCONATE (CHG) APPLICATOR HAVING EXTENDED CHG SHELF LIFE)

Market Dynamics and Financial Trajectory for CHLORAPREP TRIPLE SWABSTICK

Last updated: February 11, 2026

Market Overview
Chloraprep, an alcohol-based antiseptic with chlorhexidine gluconate, is widely used in surgical preparation. The Triple Swabstick variant of Chloraprep is designed for single-use, sterile application, primarily in preoperative skin antisepsis.

Market Size and Penetration
The global surgical antiseptics market was valued at approximately $4.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of around 5.4% through 2028[1]. Chloraprep accounts for a significant share due to its broad hospital adoption.

The sterilization and skin prep segment is expected to expand with increased surgical procedures and rising infection prevention standards. In North America, the market dominates, with an estimated 45% share, driven by high healthcare expenditure and regulation compliance.

Competitive Landscape
Main competitors include:

• Betadine (povidone-iodine) products
• Alcohol-based skin prepping solutions (e.g., Steri-Strip, Surgi-Prep)
• Generic chlorhexidine formulations

Chloraprep's triple-swabstick format is competitively positioned based on efficacy and ease of use, especially in high-volume surgical centers.

Regulatory and Reimbursement Factors
The U.S. Food and Drug Administration (FDA) approves Chloraprep for skin antisepsis. Reimbursement policies favor antiseptics with proven infection reduction benefits, creating a stable revenue environment. Insurance reimbursement codes support routine usage, influencing hospital procurement decisions.

Market Drivers

• Surge in outpatient surgeries and minimally invasive procedures, which require reliable skin antisepsis.
• Increasing compliance with infection control protocols, notably post-COVID-19 pandemic.
• Incremental adoption in emerging markets, driven by healthcare infrastructure improvements.

Market Constraints

• Price sensitivity among healthcare providers influences adoption.
• Competition from cheaper generic agents can pressure margins.
• Potential concerns over chlorhexidine-associated adverse reactions, such as skin irritation or rare hypersensitivity cases[2].

Financial Trajectory and Revenue Forecasts
The financial outlook for Chloraprep Triple Swabstick hinges on volume growth and market share retention. Key factors include:

• Sales Growth: Expected to grow at a CAGR of 4-6% over the next five years, aligning with the broader antiseptic market growth[1].

• Pricing: Slight upward pressure due to brand loyalty and formulation advantages; however, price competition remains a factor.

• Market Penetration: Increased adoption in regions like Asia-Pacific and Latin America. These markets are projected to see year-over-year growth rates exceeding 6% by 2025[3].

• Manufacturing Costs: Stable, with marginal increases due to raw material inflation (e.g., alcohol, chlorhexidine). Cost reductions through scale and manufacturing efficiency also expected.

• Profitability: Margins are stable, supported by existing patent protections and formulary acceptance. Patent expirations could influence future pricing strategies.

Pipeline and Innovation
No significant pipeline advancements specific to the Triple Swabstick format have been disclosed. Innovation focus is on expanding indications, such as antisepsis in other medical procedures, and developing single-use formats with enhanced efficacy.

Market Entry and Expansion Strategies

• Building relationships with hospital purchasing groups.
• Demonstrating superior infection prevention outcomes.
• Customizing packaging for emerging markets with local distributors.

Risks and Uncertainties

• Regulatory changes could introduce new standards for antiseptic efficacy and safety.
• Competition from alternative antiseptics with lower costs.
• Supply chain disruptions affecting raw materials.

Key Takeaways

• The Chloraprep Triple Swabstick operates within a growing, regulated antiseptic market.
• Revenue is expected to grow steadily, driven by surgical procedure volume increases and geographic expansion.
• Competitive pressures and cost factors influence pricing and margins.
• Untapped markets offer potential for increased adoption.

FAQs

1. How does the Chloraprep Triple Swabstick compare to other antiseptics?
   It combines efficacy, ease of application, and hospital familiarity, making it a preferred choice in surgical settings compared to some alternatives like povidone-iodine.

2. What are the main factors influencing its market growth?
   Procedural volume growth, infection prevention standards, and expanding healthcare infrastructure in emerging markets.

3. Are there patent protections influencing its market exclusivity?
   Yes, patents protect the specific formulation and delivery format, supporting pricing power until expiration.

4. How does competition from generics impact the financial outlook?
   Generics exert downward pressure on prices, limiting margins but still enabling volume-driven revenue growth.

5. What future innovations could affect this product line?
   Development of multi-purpose antiseptics or formulations with enhanced safety profiles may influence market dynamics.

---

Sources
[1] Grand View Research, "Surgical Antiseptics Market Size, Share & Trends," 2022.
[2] U.S. FDA, "Chlorhexidine Skin Preparation Safety," 2020.
[3] MarketsandMarkets, "Emerging Markets in Antiseptics," 2021.